NO130400B - - Google Patents
Download PDFInfo
- Publication number
- NO130400B NO130400B NO01242/70*[A NO124270A NO130400B NO 130400 B NO130400 B NO 130400B NO 124270 A NO124270 A NO 124270A NO 130400 B NO130400 B NO 130400B
- Authority
- NO
- Norway
- Prior art keywords
- groups
- isoxazolidine
- grams
- alkoxy
- carbon atoms
- Prior art date
Links
- 238000000034 method Methods 0.000 claims description 7
- 125000004423 acyloxy group Chemical group 0.000 claims description 5
- 150000001263 acyl chlorides Chemical class 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 150000002546 isoxazolidines Chemical class 0.000 claims description 4
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000005904 alkaline hydrolysis reaction Methods 0.000 claims description 2
- 125000001477 organic nitrogen group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- HPIVVOQIZYNVJE-UHFFFAOYSA-N 1,2-oxazolidin-2-ium;chloride Chemical compound Cl.C1CNOC1 HPIVVOQIZYNVJE-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000009194 climbing Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- FGPUFXOHYFCMIN-UHFFFAOYSA-N (3,4-dimethoxyphenyl)-(1,2-oxazolidin-2-yl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1OCCC1 FGPUFXOHYFCMIN-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CSLJPCFAMJCBQW-UHFFFAOYSA-N [2,6-dimethoxy-4-(1,2-oxazolidine-2-carbonyl)phenyl] acetate Chemical compound C(C)(=O)OC1=C(C=C(C(=O)N2OCCC2)C=C1OC)OC CSLJPCFAMJCBQW-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- -1 nitrogen-containing organic base Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- GUYBWIMXUDUWPX-UHFFFAOYSA-N (4-carbonochloridoyl-2,6-dimethoxyphenyl) acetate Chemical compound COC1=CC(C(Cl)=O)=CC(OC)=C1OC(C)=O GUYBWIMXUDUWPX-UHFFFAOYSA-N 0.000 description 1
- SHYLPWMBVMRXID-UHFFFAOYSA-N (4-hydroxy-3,5-dimethoxyphenyl)-(1,2-oxazolidin-2-yl)methanone Chemical compound COC=1C=C(C(=O)N2OCCC2)C=C(C1O)OC SHYLPWMBVMRXID-UHFFFAOYSA-N 0.000 description 1
- BUHYMJLFRZAFBF-UHFFFAOYSA-N 3,4,5-trimethoxybenzoyl chloride Chemical compound COC1=CC(C(Cl)=O)=CC(OC)=C1OC BUHYMJLFRZAFBF-UHFFFAOYSA-N 0.000 description 1
- VIOBGCWEHLRBEP-UHFFFAOYSA-N 3,4-dimethoxybenzoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1OC VIOBGCWEHLRBEP-UHFFFAOYSA-N 0.000 description 1
- LRLKZVMLJBNNPE-UHFFFAOYSA-N 3-(3,4,5-trimethoxyphenyl)prop-2-enamide Chemical class COC1=CC(C=CC(N)=O)=CC(OC)=C1OC LRLKZVMLJBNNPE-UHFFFAOYSA-N 0.000 description 1
- CJLIOYNRJJHMNP-UHFFFAOYSA-N 3-(4-hydroxy-3,5-dimethoxyphenyl)-1-(1,2-oxazolidin-2-yl)prop-2-en-1-one Chemical compound COC1=C(O)C(OC)=CC(C=CC(=O)N2OCCC2)=C1 CJLIOYNRJJHMNP-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- XUPSCTMGCXAJGL-UHFFFAOYSA-N [2,6-dimethoxy-4-[3-(1,2-oxazolidin-2-yl)-3-oxoprop-1-enyl]phenyl] acetate Chemical compound COC1=C(OC(C)=O)C(OC)=CC(C=CC(=O)N2OCCC2)=C1 XUPSCTMGCXAJGL-UHFFFAOYSA-N 0.000 description 1
- NIWUDNDULAYEIK-UHFFFAOYSA-N [4-(3-chloro-3-oxoprop-1-enyl)-2,6-dimethoxyphenyl] acetate Chemical compound COC1=CC(C=CC(Cl)=O)=CC(OC)=C1OC(C)=O NIWUDNDULAYEIK-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000006400 anxiety behaviour Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003010 neurosedative effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- SQMCFUSVGSBKFK-UHFFFAOYSA-M sodium;5-(cyclohexen-1-yl)-1,5-dimethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].O=C1N(C)C(=O)[N-]C(=O)C1(C)C1=CCCCC1 SQMCFUSVGSBKFK-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Analogifremgangsmåte for fremstilling av Analogy method for the production of
terapeutisk aktive isoxazolidinderivater. therapeutically active isoxazolidine derivatives.
Foreliggende oppfinnelse angår en analogifremgangsmåte for fremstilling av nye isoxazolidinder ivater med d-en generelle formel: The present invention relates to an analogous process for the production of new isoxazolidine derivatives with d-a general formula:
hvor n er 0 eller 1, og F^, F?2 og R uavhengig representerer en hydroksy-, alkoksy- eller alkanoyloksygruppe med 1-4 karbonatomer, og hvor en av disse grupper kan være hydrogen. where n is 0 or 1, and F^, F^2 and R independently represent a hydroxy, alkoxy or alkanoyloxy group with 1-4 carbon atoms, and where one of these groups may be hydrogen.
De nye isoxåzolidinforbindelser virker på sentralnervesystemet, noe som indikeres ved deres effektivitet i stangklatringsunngåelsesprøver på rotter. De nye forbindelser er ganske enestående ved at de viser meget høy grad av aktivitet i nevnte prøver, mens de praktisk talt ikke har noen aktivitet nåi? de prøves for psyko-sedative og neuro-depressive effekter på mus. Denne egenskap sammen med meget lav toksitet, gjør at forbindelsene kan klassifiseres som selektivt psyko-aktive. Forbindelsene påvirker med andre ord angstoppførselen uten å svekke bevisstheten og uten muskeleffekter. Forbindelser som ligner de med den ovenfor angitte formel I er kjent fra US-patent 3-268.407, og som eksempel kan nevnes 3,4,5-trimetoksykanelsyre-amider hvilke virker på sentralnervesystemet som generiske depresjons-midler. The new isoxazolidine compounds act on the central nervous system, as indicated by their efficacy in rat pole-climbing avoidance tests. The new compounds are quite unique in that they show a very high degree of activity in said samples, while they have practically no activity in they are tested for psycho-sedative and neuro-depressive effects on mice. This property, together with very low toxicity, means that the compounds can be classified as selectively psychoactive. In other words, the compounds affect anxiety behavior without impairing consciousness and without muscle effects. Compounds similar to those with the formula I stated above are known from US patent 3-268,407, and as an example can be mentioned 3,4,5-trimethoxycinnamic acid amides which act on the central nervous system as generic depressants.
De nye forbindelser med formel I fremstilles ifølge oppfinnelsen ved at isoxazolidin enten i form av en fri base eller i form av syreaddisjonssalter med syrer, omsettes med et acylklorid The new compounds of formula I are prepared according to the invention by reacting isoxazolidine, either in the form of a free base or in the form of acid addition salts with acids, with an acyl chloride
med formel with formula
hvor n har samme betydning som angitt ovenfor, og R^, R^ og Rg uavhengig representerer alkoksy- eller alkanoyloksygrupper med 1-4 karbonatomer og hvor en av disse grupper kan være hydrogen,' i nærvær av en organisk nitrogenbase. Reaksjonen utføres i et organisk, vannfritt oppløsningsmiddel. Reaksjonen skjer ved temperaturer fra ca. 0°C til blandingens kokepunkt. Romtemperatur bør fortrinnsvis anvendes som den nedre grense. where n has the same meaning as stated above, and R^, R^ and Rg independently represent alkoxy or alkanoyloxy groups with 1-4 carbon atoms and where one of these groups may be hydrogen,' in the presence of an organic nitrogen base. The reaction is carried out in an organic, anhydrous solvent. The reaction takes place at temperatures from approx. 0°C to the boiling point of the mixture. Room temperature should preferably be used as the lower limit.
Mengden av reagenser er ikke kritisk, men man oppnår imidlertid de beste resultater når man bruker i alt vesentlig ekvi-molare mengder av isoxazolidinet og acylkloridet, mens den nitrogen-holdige organiske base tilsettes i mer eller mindre overskudd, fortrinnsvis i et forhold på 1,1 - 1,5 mol for hver ekvivalent av totalt tilstedeværende syre ved slutten av reaksjonen. Når en eller flere av substituentene i benzenringen i utgangsacylkloridet er alkanoyloksygrupper, så kan den fremstilte forbindelse eventuelt underkastes alkalisk hydrolyse, hvorved acylgruppene avspaltes og man oppnår det tilsvarende fénol. Dette trinn utføres ifølge vanlige fremgangsmåter, f.eks. ved å anvende et overskudd av- en base valgt fra gruppen bestående av ammoniumhydroksyd og alkalimetallhydroksyder 1 et vandig medium. Man har imidlertid også funnet.å kunne anvende organiske baser. The amount of reagents is not critical, but the best results are obtained when essentially equimolar amounts of the isoxazolidine and the acyl chloride are used, while the nitrogen-containing organic base is added in more or less excess, preferably in a ratio of 1, 1 - 1.5 mol for each equivalent of total acid present at the end of the reaction. When one or more of the substituents in the benzene ring in the starting acyl chloride are alkanoyloxy groups, the compound produced can optionally be subjected to alkaline hydrolysis, whereby the acyl groups are split off and the corresponding phenol is obtained. This step is carried out according to usual methods, e.g. by using an excess of a base selected from the group consisting of ammonium hydroxide and alkali metal hydroxides in an aqueous medium. However, it has also been found to be able to use organic bases.
Følgende eksempler illustrerer oppfinnelsen. The following examples illustrate the invention.
E ksempel 1 Example 1
2 - ( 5, 4, 5- trimetoksybenzoyl)- isoxazolidin 2-(5,4,5-trimethoxybenzoyl)-isoxazolidine
219,1 gram isoxazolidinhydroklorid oppløst i 3,5 liter metylenklorid ble langsomt tilsatt 620 ml trietylamin. Etter røring i 15 minutter ble 461 gram 3,4,5-trimetoksybenzoylklorid i 2,2 liter metylenklorid tilsatt i løpet av 40 minutter samtidig som tempera-turen ble holdt under 30°C. Reaksjonen ble først utført ved romtemperatur i 1 time under omrøring, og så under tilbakeløp i 2 timer til. Blandingen ble avkjølt, vasket med vann, 5%'s saltsyre, 5%'s natriumbikarbonat og endelig med vann til nøytralitet. Den organiske fase ble utskilt, tørket over natriumsulfat hvoretter oppløsnings-midlet ble fradestillert i vakuum. Resten som besto av 2-(3,4,5-trimetoksybenzoyD-isoxazolidin, ble utkrystallisert fra diisopropyl-eter. Utbytte 470 gram (88,0%), smeltepunkt 75-76°C. 219.1 grams of isoxazolidine hydrochloride dissolved in 3.5 liters of methylene chloride was slowly added to 620 ml of triethylamine. After stirring for 15 minutes, 461 grams of 3,4,5-trimethoxybenzoyl chloride in 2.2 liters of methylene chloride were added over the course of 40 minutes while keeping the temperature below 30°C. The reaction was first carried out at room temperature for 1 hour with stirring, and then under reflux for a further 2 hours. The mixture was cooled, washed with water, 5% hydrochloric acid, 5% sodium bicarbonate and finally with water to neutrality. The organic phase was separated, dried over sodium sulphate after which the solvent was distilled off in vacuo. The residue consisting of 2-(3,4,5-trimethoxybenzoyD-isoxazolidine) was crystallized from diisopropyl ether. Yield 470 grams (88.0%), mp 75-76°C.
Analyse: Analysis:
Eksem pel 2 2-( 3, 4- dimetoksybenzoyl)- isoxazolidin Ved samme fremgangsmåte som i eksempel 1, ble 2-(3,4-dimetoksybenzoyl)-isoxazolidin fremstilt ved å tilsette 6,1 gram 3,4-dimetoksybenzoylklorid oppløst i 107 ml metylenklorid til en suspensjon av 3,92 gram isoxazolidinhydroklorid og 10,2 ml trietylamin i 72 ml metylenklorid. Utbytte 4,4 gram (60,7%), smeltepunkt 87,5-88,5°€. Analyse: Example 2 2-(3,4-dimethoxybenzoyl)-isoxazolidine Using the same method as in example 1, 2-(3,4-dimethoxybenzoyl)-isoxazolidine was prepared by adding 6.1 grams of 3,4-dimethoxybenzoyl chloride dissolved in 107 ml of methylene chloride to a suspension of 3.92 grams of isoxazolidine hydrochloride and 10.2 ml of triethylamine in 72 ml of methylene chloride. Yield 4.4 grams (60.7%), melting point 87.5-88.5°€. Analysis:
Eksempel 3 Example 3
2 - ( 4- acetoksy-- 3, 5- dimetoksybenzoyl )- isoxazolidin 2 - ( 4- acetoxy-- 3, 5- dimethoxybenzoyl )- isoxazolidine
Denne forbindelse ble fremstilt ved samme fremgangsmåte som i eksempel r idet man anvendte 4,65 gram isoxazolidinhydroklorid, 14,3 ml trietylamin og 11 gram 4-acetoksy-3,-5-dimetoksybenzoylklorid. Utbytte 10 gram (81,7%), smeltepunkt 120-121°C. This compound was prepared by the same method as in example r, using 4.65 grams of isoxazolidine hydrochloride, 14.3 ml of triethylamine and 11 grams of 4-acetoxy-3,-5-dimethoxybenzoyl chloride. Yield 10 grams (81.7%), melting point 120-121°C.
Analyse: Analysis:
Eksempel 4 Example 4
2-( 4- acetoksy- 3, 5~ d imetoksyc innamoyl)- isoxazolidin 2-( 4- acetoxy- 3, 5~ dimethoxyc innamoyl)- isoxazolidine
Dette stoff ble fremstilt som beskrevet i eksempel 1, idet man anvendte 2,96 gram isoxazolidinhydroklorid, 9,1 ml trietylamin og 7,7 gram 4-acetoksy-3,5-dimetoksycinnamoylklorid. Utbytte 5,9 gram (68,0%), smeltepunkt 155-156°C. This substance was prepared as described in example 1, using 2.96 grams of isoxazolidine hydrochloride, 9.1 ml of triethylamine and 7.7 grams of 4-acetoxy-3,5-dimethoxycinnamoyl chloride. Yield 5.9 grams (68.0%), melting point 155-156°C.
Analyse: Analysis:
Eksempel 5 Example 5
2-( 3, 5~ dimetoksy- 4- hydroksybenzoyl)- isoxazolidin 2-(3,5~dimethoxy-4-hydroxybenzoyl)-isoxazolidine
4 .gram 2-(4-acetoksy-3,5-dimetoksybenzoyl)-isoxazolidin ble suspendert i '40 ml vann og 20 ml konsentrert ammoniakkoppløsning. Suspensjonen ble oppvarmet til ca. 80°C hvorved man fikk en full-stendig oppløsning av det faste stoff. Den varme væske ble filtrert og bragt til pH 7 med fortynnet saltsyre, deretter avkjølt på is i 2 timer. De dannede krystaller som bestod av 2-(3,5~dimetoksy-4-hydroksybenzoy1)-isoxazolidin, ble oppsamlet ved filtrering og tørket over fosforpentoksyd. Utbytte 2,68 gram (78,1%), smeltepunkt 75~ 76°C. Analyse: 4 grams of 2-(4-acetoxy-3,5-dimethoxybenzoyl)-isoxazolidine were suspended in 40 ml of water and 20 ml of concentrated ammonia solution. The suspension was heated to approx. 80°C whereby a complete dissolution of the solid was obtained. The hot liquid was filtered and brought to pH 7 with dilute hydrochloric acid, then cooled on ice for 2 hours. The formed crystals consisting of 2-(3,5-dimethoxy-4-hydroxybenzoyl)-isoxazolidine were collected by filtration and dried over phosphorus pentoxide. Yield 2.68 grams (78.1%), mp 75~76°C. Analysis:
Eksempel 6 Example 6
2-( 3, 5~ dimetoksy- 4- hydroksycinnamoyl)- isoxazolidin 2-( 3, 5~ dimethoxy- 4- hydroxycinnamoyl)- isoxazolidine
2,56 gram 2-(4-acetoksy-3,5-dimetoksycinnamoyl)-isoxazolidin ble suspendert i en blanding av 3,6 ml vann, 4 ml konsentrert ammoniakkoppløsning og 20 ml etanol. Suspensjonen ble holdt på 60°C i 2 timer, justert i varm tilstand til pH 7 og så avkjølt på is i 3 timer. Det dannede bunnfall som bestod av 2-(3,5-dimetoksy-4-hydroksycinnamoyl)-isoxazolidin ble oppsamlet og tørket som beskrevet ovenfor. Utbytte 2,1 gram (94,4%), smeltepunkt l66-l67°C. 2.56 grams of 2-(4-acetoxy-3,5-dimethoxycinnamoyl)-isoxazolidine was suspended in a mixture of 3.6 ml of water, 4 ml of concentrated ammonia solution and 20 ml of ethanol. The suspension was held at 60°C for 2 hours, adjusted while hot to pH 7 and then cooled on ice for 3 hours. The precipitate formed consisting of 2-(3,5-dimethoxy-4-hydroxycinnamoyl)-isoxazolidine was collected and dried as described above. Yield 2.1 grams (94.4%), melting point 166-167°C.
Analyse: Analysis:
Som nevnt ovenfor ble det nervøse utslag for de nye forbindelser indikert ved stangklatringsunngåelsesprøven på rotter. Denne prøve ble utført som beskrevet av Cook og V/eidley i Annals N. As mentioned above, the nervous response to the new compounds was indicated by the pole-climbing avoidance test in rats. This test was carried out as described by Cook and V/eidley in Annals N.
Y. Acad. Sei. 66 7^0 (1957 )., med noen modifikasjoner slik dette Y. Acad. Pollock. 66 7^0 (1957 )., with some modifications like this
er beskrevet av Maffii i J. Pharm. Pharmacol. 11 129 (1959)- is described by Maffii in J. Pharm. Pharmacol. 11 129 (1959)-
Apparatet består av en varme- og lydisolert boks utstyrt med en The device consists of a heat- and sound-insulated box equipped with a
rist av stålstaver som gulv, og disse er forbundet med en elektrisk stimulator. Boksen inneholder også en lydkilde, samt en trestand i midten som utgjør det trygge område. Rottene unngår de elektriske sjokk ved å klatre opp stangen. Etter at rottene er sluppet inn i boksen blir de underkastet følgende prøving: 15 sekunders stillhet, 15 sekunders akustisk stimulering, 30 sekunder av både elektrisk og akustisk stimulering. Når .dyret reagerer blir prøvingen avsluttet. Klatring på trestangen under den stille periode kalles CR^Csekunder betinget respons), klatring på stangen under den akustiske stimulering kalles CR^ (primær betinget respons) og klatring under den elektriske stimulering kall.es UR (ubetinget respons). tolkes som en nervøs reaksjon. grid of steel rods as a floor, and these are connected to an electrical stimulator. The box also contains a sound source, as well as a wooden stand in the middle which forms the safe area. The rats avoid the electric shocks by climbing the pole. After the rats are released into the box, they are subjected to the following test: 15 seconds of silence, 15 seconds of acoustic stimulation, 30 seconds of both electrical and acoustic stimulation. When the animal reacts, the test is terminated. Climbing the wooden pole during the silent period is called CR^Cseconds conditioned response), climbing the pole during the acoustic stimulation is called CR^ (primary conditioned response) and climbing during the electrical stimulation is called UR (unconditioned response). interpreted as a nervous reaction.
Manglen på .psykosedative, neurosedative og neurovegeta-tive effekter hos de nye forbindelser ble fastslått gjennom en observasjon av mus ifølge det prøveskjema 'som er angitt av Irwin, Gordon Res. Conf. Med. Chem., New London, N.M. 3-7/8, 133 (1959). The lack of psychosedative, neurosedative and neurovegetative effects in the new compounds was established through an observation of mice according to the test schedule set forth by Irwin, Gordon Res. Conf. With. Chem., New London, N.M. 3-7/8, 133 (1959).
Denne fremgangsmåte innbefatter at man systematisk observerer .grupper This procedure includes systematically observing groups
på 3 mus pr. dose, og hvor disse behandles méd økende doser av stoffet. De observerte forandringer blir så notert. of 3 mice per dose, and where these are treated with increasing doses of the substance. The observed changes are then noted.
Manglende effekt på arterietrykket ..ble målt i halspuls- Lack of effect on arterial pressure ..was measured in carotid pulse-
åren hos katter under, bedøvelse ved hjelp av natriumheksobarbital, vein in cats during, anesthesia with sodium hexobarbital,
'40 mg pr. kg intraper itonalt. Produktene ble injisert i den femurale arterie. En minimumssenkning på 20% i trykket i løpet av minst 20 minutter ble ansett som betydelig. '40 mg per kg intraper itonally. The products were injected into the femoral artery. A minimum reduction of 20% in pressure over at least 20 minutes was considered significant.
Resultatene i mg/kg for en del representative forbindelser The results in mg/kg for some representative compounds
er angitt i tabell I.- is indicated in table I.-
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1600069 | 1969-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO130400B true NO130400B (en) | 1974-08-26 |
Family
ID=11148429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO01242/70*[A NO130400B (en) | 1969-04-24 | 1970-04-03 |
Country Status (13)
Country | Link |
---|---|
AT (1) | AT296294B (en) |
BE (1) | BE748711A (en) |
BR (1) | BR6915476D0 (en) |
CH (1) | CH541570A (en) |
DE (1) | DE2019659A1 (en) |
ES (1) | ES378999A1 (en) |
FI (1) | FI49305C (en) |
FR (1) | FR2042369B1 (en) |
GB (1) | GB1243767A (en) |
IL (1) | IL34190A (en) |
NL (1) | NL146497B (en) |
NO (1) | NO130400B (en) |
SE (1) | SE349584B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3853903A (en) * | 1972-08-17 | 1974-12-10 | Lepetit Spa | Substituted 2 -benzoylisoxazolidines |
-
1969
- 1969-12-19 BR BR215476/69A patent/BR6915476D0/en unknown
-
1970
- 1970-03-20 GB GB03637/70A patent/GB1243767A/en not_active Expired
- 1970-03-26 FI FI700871A patent/FI49305C/en active
- 1970-03-29 IL IL34190A patent/IL34190A/en unknown
- 1970-04-03 NO NO01242/70*[A patent/NO130400B/no unknown
- 1970-04-09 BE BE748711D patent/BE748711A/en unknown
- 1970-04-16 NL NL707005470A patent/NL146497B/en unknown
- 1970-04-22 AT AT368570A patent/AT296294B/en not_active IP Right Cessation
- 1970-04-23 FR FR707014841A patent/FR2042369B1/fr not_active Expired
- 1970-04-23 DE DE19702019659 patent/DE2019659A1/en active Pending
- 1970-04-23 CH CH612170A patent/CH541570A/en not_active IP Right Cessation
- 1970-04-23 SE SE05641/70A patent/SE349584B/xx unknown
- 1970-04-24 ES ES378999A patent/ES378999A1/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
CH541570A (en) | 1973-09-15 |
AT296294B (en) | 1972-02-10 |
IL34190A0 (en) | 1970-08-19 |
GB1243767A (en) | 1971-08-25 |
NL146497B (en) | 1975-07-15 |
FI49305C (en) | 1975-05-12 |
BE748711A (en) | 1970-09-16 |
IL34190A (en) | 1974-03-14 |
FR2042369A1 (en) | 1971-02-12 |
FI49305B (en) | 1975-01-31 |
FR2042369B1 (en) | 1973-06-08 |
ES378999A1 (en) | 1973-01-16 |
BR6915476D0 (en) | 1973-02-08 |
DE2019659A1 (en) | 1970-10-29 |
SE349584B (en) | 1972-10-02 |
NL7005470A (en) | 1970-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3963729A (en) | Pharmacologically active pyridine derivatives | |
US2831027A (en) | Isocamphane compounds and processes for preparing the same | |
EP0007019A1 (en) | 5-Phenyl-pyrazole derivatives and their salts, processes for their preparation and medicines containing them | |
EP0005231A2 (en) | Isoquinoline derivatives, process for their preparation and pharmaceutical preparations containing them | |
EP0133530A2 (en) | 1,6-Naphthyridinone derivatives, process for their preparation, and medicaments containing them | |
CH506525A (en) | Aromatic ethers | |
SU722481A3 (en) | Method of preparing aminoketone derivatives or their salts | |
US2503285A (en) | Beta-substituted alpha, beta-diphenylethylamines and the preparation thereof | |
NO130400B (en) | ||
NO300839B1 (en) | New 2-cyano-3-hydroxy-propenamides and pharmaceutical preparations containing such | |
NO152786B (en) | PROCEDURE FOR PREPARING 10,11-DIHYDRO-5H-DIBENZO- (A, D) -CYCLOHEPTEN-5,10-IMINES | |
NO149314B (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF PHYSIOLOGICALLY ACTIVE IMIDAZOISOKINOL INDIONS | |
NO155056B (en) | EXPLOSIVES. | |
DD154487A5 (en) | PROCESS FOR THE PREPARATION OF 1-BENZOXEPIN-5 (2H) -ONE DERIVATIVES | |
NO162017B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE ALFA-ARYL-ALFA-PYRIDYLALKANIC ACID DERIVATIVES. | |
US4013667A (en) | 2,2-Diaryl-3-(1-azabicyclo[2.2.2]oct-2-yl)propionamides and intermediates thereto | |
CH637951A5 (en) | 3-PYRAZOL-1-YL-PYRIDAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAL PREPARATIONS CONTAINING THESE COMPOUNDS. | |
Shaw et al. | Analogs of Aspergillic Acid. III. Synthesis of Cyclic Hydroxamic Acids with a Five-membered Ring | |
NO770014L (en) | PROCEDURES FOR THE PREPARATION OF HYDROAZINE DERIVATIVES. | |
CH669196A5 (en) | TRIAZOLOPYRIMIDINE AND METHOD FOR THE PRODUCTION THEREOF. | |
CH641457A5 (en) | AZEPINO (1,2,3-LM) BETA CARBOLIN COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THE COMPOUNDS. | |
US3378592A (en) | Process for the production of 3, 4-dihydroxybenzyloxyaminehydrobromide | |
DE2151487A1 (en) | Pharmaceutical masses | |
EP0004322A1 (en) | Isoquinolines, process for their preparation and their use for the preparation of medicines | |
SU1329620A3 (en) | Method of producing isoquinoline or pharmaceutically acceptable additive acid salts thereof |